Inhibition of the Receptor for Advanced Glycation End Products Enhances the Cytotoxic Effect of Gemcitabine in Murine Pancreatic Tumors

Pancreatic ductal adenocarcinoma (PDAC) remains a very difficult cancer to treat. Recent in vitro and in vivo studies suggest that the activation of the receptor for advanced glycation end products (RAGE) by its ligands stimulates pancreatic cancer cell proliferation and tumor growth. Additional stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Swami, Priyanka, O’Connell, Kelly A., Thiyagarajan, Swetha, Crawford, Ayrianne, Patil, Prathamesh, Radhakrishnan, Prakash, Shin, Simon, Caffrey, Thomas C., Grunkemeyer, James, Neville, Tammi, Vetter, Stefan W., Hollingsworth, Michael A., Leclerc, Estelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067004/
https://www.ncbi.nlm.nih.gov/pubmed/33915939
http://dx.doi.org/10.3390/biom11040526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067004/
https://www.ncbi.nlm.nih.gov/pubmed/33915939
http://dx.doi.org/10.3390/biom11040526

Ejemplares similares